Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

The Max Foundation is proud to announce that our Chief Executive Officer Pat Garcia-Gonzalez has been named a finalist for the Union for International Cancer Control (UICC)’s CEO Award!

Pat is one of three finalists for this year’s award, alongside two friends and compatriots in the fight against cancer: Asem Mansour of King Hussein Cancer Center in Jordan, and Wondu Bekele Woldemariam of Mathiwos Wondu-YeEthiopia Cancer Society. Our thanks and congratulations go out to all three finalists for their tremendous impact and visionary leadership. The world is a better place for their contributions.

We would also like to thank the 18 different Patient Associations from around the world that sent letters in support of Pat’s nomination. You are the inspiration for all we do and we are so very grateful for your support.

The winner of the award will be announced on October 2nd at this year’s World Cancer Congress in Kuala Lumpur. Representatives from The Max Foundation and patient advocates from across Asia will be in attendance to share their knowledge, their experiences, and, of course, to cheer on Pat!

Visit the UICC website to learn more about the awards and the finalists.

 

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    Building on two decades of progress, Max’s ambitious goal will expand its proven, patient-centered model that has already helped more than 100,000 people access treatment Commitment will enhance local health system capabilities to deliver innovative and generic medicines, diagnostics, and treatment in more than 80 low- and middle-income countries Alongside this commitment, Max and Novartis sign….

  • The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)

    The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….

  • The Max Foundation and Tanner Pharma partner on innovative drug distribution model

    The Max Foundation and Tanner Pharma Group have partnered to create an innovative distribution model to deliver oncology products to patients in need.